{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:16:41Z","timestamp":1793686601514,"version":"4.5.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/25\/B\/NZ7\/02654"],"award-info":[{"award-number":["2017\/25\/B\/NZ7\/02654"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.biopha.2022.112695","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T16:15:52Z","timestamp":1644596152000},"page":"112695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Pharmacological assessment of zebrafish-based cardiotoxicity models"],"prefix":"10.1016","volume":"148","author":[{"given":"Monika","family":"Maciag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Wnorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mierzejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Plazinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2022.112695_bib1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12872-018-0858-5","article-title":"Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries","volume":"18","author":"Bazargani","year":"2018","journal-title":"BMC Cardiovasc. Disord."},{"issue":"8","key":"10.1016\/j.biopha.2022.112695_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/2472555218775028","article-title":"Clinical trials in a dish: a perspective on the coming revolution in drug development","volume":"23","author":"Fermini","year":"2018","journal-title":"SLAS Discov."},{"issue":"7","key":"10.1016\/j.biopha.2022.112695_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"25","key":"10.1016\/j.biopha.2022.112695_bib5","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.115.020723","article-title":"The future of clinical trials in cardiovascular medicine","volume":"133","author":"Solomon","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2022.112695_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1152\/physrev.00038.2016","article-title":"Little fish, big data: zebrafish as a model for cardiovascular and metabolic disease","volume":"97","author":"Gut","year":"2017","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib7","doi-asserted-by":"crossref","first-page":"16243","DOI":"10.1038\/s41598-020-73455-9","article-title":"Edible additive effects on zebrafish cardiovascular functionality with hydrodynamic assessment","volume":"10","author":"Wang","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib8","first-page":"9","article-title":"The zebrafish model system in cardiovascular research: a tiny fish with mighty prospects","volume":"2013","author":"Poon","year":"2013","journal-title":"Glob. Cardiol. Sci. Pract."},{"issue":"3","key":"10.1016\/j.biopha.2022.112695_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ddmod.2009.02.003","article-title":"Zebrafish as a model for cardiovascular development and disease","volume":"5","author":"Nguyen","year":"2008","journal-title":"Drug Discov. Today Dis. Models"},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib10","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1038\/srep04898","article-title":"ZebraBeat: a flexible platform for the analysis of the cardiac rate in zebrafish embryos","volume":"4","author":"De Luca","year":"2014","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2022.112695_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pharmthera.2013.10.007","article-title":"Small and large animal models in cardiac contraction research: advantages and disadvantages","volume":"141","author":"Milani-Nejad","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2022.112695_bib12","doi-asserted-by":"crossref","first-page":"a006684","DOI":"10.1101\/cshperspect.a006684","article-title":"Vascular development in the zebrafish","volume":"2","author":"Gore","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2022.112695_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-213X-10-3","article-title":"The role of vasculature and blood circulation in zebrafish swimbladder development","volume":"10","author":"Winata","year":"2010","journal-title":"BMC Dev. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2022.112695_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098131","article-title":"Podocyte developmental defects caused by adriamycin in zebrafish embryos and larvae: a novel model of glomerular damage","volume":"9","author":"Zennaro","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2022.112695_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.069","article-title":"Blood flow limits endothelial cell extrusion in the zebrafish dorsal aorta","volume":"31","author":"Campinho","year":"2020","journal-title":"Cell Rep."},{"issue":"13","key":"10.1016\/j.biopha.2022.112695_bib16","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cbic.201900741","article-title":"Cyp1 inhibition prevents doxorubicin-induced cardiomyopathy in a zebrafish heart-failure model","volume":"21","author":"Lam","year":"2020","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96753","article-title":"Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity","volume":"3","author":"Asnani","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.biopha.2022.112695_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s43018-020-0039-1","article-title":"A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy","volume":"1","author":"Amgalan","year":"2020","journal-title":"Nat. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2022.112695_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure: pathophysiology and therapy","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2022.112695_bib20","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112695_bib21","first-page":"18","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardiooncology"},{"issue":"4","key":"10.1016\/j.biopha.2022.112695_bib22","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/j.1476-5381.2012.01880.x","article-title":"Does terfenadine-induced ventricular tachycardia\/fibrillation directly relate to its QT prolongation and Torsades de Pointes?","volume":"166","author":"Lu","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.biopha.2022.112695_bib23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/cvr\/cvz161","article-title":"Small animal models of heart failure","volume":"115","author":"Riehle","year":"2019","journal-title":"Cardiovasc. Res"},{"key":"10.1016\/j.biopha.2022.112695_bib24","unstructured":"OECD, Test No. 236: Fish Embryo Acute Toxicity (FET) Test, 2013."},{"key":"10.1016\/j.biopha.2022.112695_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.micron.2020.102876","article-title":"Cardiac function and blood flow hemodynamics assessment of zebrafish (Danio rerio) using high-speed video microscopy","volume":"136","author":"Benslimane","year":"2020","journal-title":"Micron"},{"key":"10.1016\/j.biopha.2022.112695_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.chemosphere.2018.01.045","article-title":"Novel procedures for whole organism detection and quantification of fluorescence as a measurement for oxidative stress in zebrafish (Danio rerio) larvae","volume":"197","author":"Lackmann","year":"2018","journal-title":"Chemosphere"},{"issue":"4","key":"10.1016\/j.biopha.2022.112695_bib27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.celrep.2016.06.033","article-title":"Developmental apoptosis mediates entry and positioning of microglia in the zebrafish brain","volume":"16","author":"Casano","year":"2016","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.biopha.2022.112695_bib28","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-8703(81)90378-1","article-title":"Inotropic responsiveness of the heart in catecholamine cardiomyopathy","volume":"101","author":"Fripp","year":"1981","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.biopha.2022.112695_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-8703(85)90597-6","article-title":"Coronary vasoconstriction and catecholamine cardiomyopathy","volume":"109","author":"Simons","year":"1985","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2022.112695_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/795602","article-title":"Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress","volume":"2015","author":"Angsutararux","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.biopha.2022.112695_bib32","first-page":"235","volume":"3","author":"Lip","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"19","key":"10.1016\/j.biopha.2022.112695_bib33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.biopha.2022.112695_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11936-020-00842-w","article-title":"Doxorubicin cardiotoxicity: pathophysiology updates","volume":"22","author":"Hoeger","year":"2020","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"issue":"266","key":"10.1016\/j.biopha.2022.112695_bib35","doi-asserted-by":"crossref","first-page":"266ra170","DOI":"10.1126\/scitranslmed.3010189","article-title":"Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase","volume":"6","author":"Liu","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2022.112695_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122123","article-title":"Zebrafish as a vertebrate model system to evaluate effects of environmental toxicants on cardiac development and function","volume":"17","author":"Sarmah","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s42003-020-01440-z","article-title":"Early detection of doxorubicin-induced cardiotoxicity in rats by its cardiac metabolic signature assessed with hyperpolarized MRI","volume":"3","author":"Timm","year":"2020","journal-title":"Commun. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2022.112695_bib38","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1242\/dmm.016170","article-title":"The zebrafish as a tool to identify novel therapies for human cardiovascular disease","volume":"7","author":"Asnani","year":"2014","journal-title":"Dis. Models Mech."},{"issue":"2","key":"10.1016\/j.biopha.2022.112695_bib39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jtcvs.2010.07.097","article-title":"Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function","volume":"142","author":"Hiona","year":"2011","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"4","key":"10.1016\/j.biopha.2022.112695_bib40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.112695_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2015.12.008","article-title":"SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy","volume":"205","author":"Cappetta","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2022.112695_bib42","doi-asserted-by":"crossref","first-page":"H2441","DOI":"10.1152\/ajpheart.00005.2005","article-title":"Differential cardioprotective\/cardiotoxic effects mediated by beta-adrenergic receptor subtypes","volume":"289","author":"Bernstein","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.biopha.2022.112695_bib43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1472-8206.2004.00282.x","article-title":"Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats","volume":"18","author":"Thomas","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2022.112695_bib44","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1124\/jpet.115.225375","article-title":"Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy","volume":"355","author":"Chen","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/AC.67.1.2146570","article-title":"Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia\/reperfusion injury as well as doxorubicin cardiotoxicity","volume":"67","author":"Bozcali","year":"2012","journal-title":"Acta Cardiol."},{"issue":"13","key":"10.1016\/j.biopha.2022.112695_bib46","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension","volume":"71","author":"Messerli","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112695_bib47","article-title":"Evaluation of \u03b2-adrenergic ligands for development of pharmacological heart failure and transparency models in zebrafish","author":"Maciag","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0022-3565(25)38340-0","article-title":"Protective effect of clentiazem against epinephrine-induced cardiac injury in rats","volume":"266","author":"Deisher","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.112695_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1071-9164(99)90033-7","article-title":"Hemodynamic changes and neurohumoral regulation during development of congestive heart failure in a model of epinephrine-induced cardiomyopathy in conscious rabbits","volume":"5","author":"Muders","year":"1999","journal-title":"J. Card. Fail."},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0167-5273(92)90105-C","article-title":"Effect of diltiazem on norepinephrine-induced acute left ventricular dysfunction","volume":"36","author":"Jolly","year":"1992","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.biopha.2022.112695_bib51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/hr.2009.28","article-title":"Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates","volume":"32","author":"Izumi","year":"2009","journal-title":"Hypertens. Res."},{"issue":"3\u20134","key":"10.1016\/j.biopha.2022.112695_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1242\/dmm.005017","article-title":"Heart failure and mouse models","volume":"3","author":"Breckenridge","year":"2010","journal-title":"Dis. Models Mech."},{"issue":"6","key":"10.1016\/j.biopha.2022.112695_bib53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10741-014-9418-y","article-title":"Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity","volume":"19","author":"Liaudet","year":"2014","journal-title":"Heart Fail. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2022.112695_bib54","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"13","key":"10.1016\/j.biopha.2022.112695_bib55","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1161\/01.CIR.0000092166.30360.78","article-title":"Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo","volume":"108","author":"Barki-Harrington","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2022.112695_bib56","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12012-011-9108-0","article-title":"Valsartan, an angiotensin II receptor blocker, attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity","volume":"11","author":"Goyal","year":"2011","journal-title":"Cardiovasc. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2022.112695_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12012-020-09590-6","article-title":"The protective effects of compound 21 and valsartan in isoproterenol-induced myocardial injury in rats","volume":"21","author":"Ulutas","year":"2021","journal-title":"Cardiovasc. Toxicol."},{"issue":"3","key":"10.1016\/j.biopha.2022.112695_bib58","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.taap.2003.07.012","article-title":"Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia","volume":"193","author":"Langheinrich","year":"2003","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2022.112695_bib59","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/sj.bjp.0706493","article-title":"Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias","volume":"147","author":"Takahara","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2022.112695_bib60","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4070\/kcj.2017.0080","article-title":"Zebrafish larvae model of dilated cardiomyopathy induced by terfenadine","volume":"47","author":"Gu","year":"2017","journal-title":"Korean Circ. J."},{"issue":"4","key":"10.1016\/j.biopha.2022.112695_bib61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10557-010-6247-7","article-title":"Which beta-blocker is most effective in heart failure?","volume":"24","author":"Remme","year":"2010","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.biopha.2022.112695_bib62","doi-asserted-by":"crossref","DOI":"10.3904\/kjim.2019.038","article-title":"Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure","author":"Quan","year":"2020","journal-title":"Korean J. Intern. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222200083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222200083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:38:21Z","timestamp":1781764701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222200083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":62,"alternative-id":["S075333222200083X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112695","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological assessment of zebrafish-based cardiotoxicity models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112695"}}